Evista (raloxifene) is now approved to TREAT osteoporosis
November 1999
Evista (raloxifene) is now approved to TREAT osteoporosis...it used to be approved only for prevention.
Evista decreases vertebral fractures up to 50%...in postmenopausal women who take it for 3 years.
This is comparable to the decrease in vertebral fractures that's seen with Fosamax (alendronate)...even though Evista doesn't increase bone density as much as Fosamax.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote